Literature DB >> 25104099

Association of Toll-like Receptor 4 Gene polymorphisms with susceptibility to type 2 diabetes mellitus in the Chinese population.

Danfeng Peng1, Feng Jiang1, Rong Zhang1, Shanshan Tang1, Miao Chen1, Jing Yan1, Xue Sun1, Yi Luo1, Cheng Hu1, Weiping Jia1.   

Abstract

BACKGROUND: Toll-like receptor 4 (TLR4) plays an important role in innate immunity. Activation of innate immune response and subsequent chronic low-grade inflammation are thought to be involved in the pathogenesis of type 2 diabetes. In this study, we aimed to investigate the association of TLR4 variants with type 2 diabetes in the Chinese population.
METHODS: Seven tag single nucleotide polymorphisms (SNPs) of TLR4 based on HapMap Chinese data were genotyped in the Shanghai Chinese, including 3404 type 2 diabetes patients and 3401 controls. The controls were extensively phenotyped for the traits related to glucose metabolism and insulin secretion.
RESULTS: In total participants, we identified that rs10759932 and rs1927911 were associated with type 2 diabetes (odds ratio 1.106, P = 0.009 for rs10759532, odds ratio 1.092, P = 0.013 for rs1927911). rs11536889 showed a trend association with type 2 diabetes (odds ratio 0.957, P = 0.057). This SNP was also associated with 2-h plasma glucose (P = 0.033) and high-density lipoprotein-cholesterol (P = 0.031). In female participants, rs10759932, rs1927911 and rs11536889 were associated with type 2 diabetes (odds ratio 1.176, P = 0.002 for rs10759932, odds ratio 1.136, P = 0.009 for rs1927911, odds ratio 0.882, P = 0.024 for rs11536889). Besides, rs11536889 was significantly associated with 2-h plasma glucose (P = 0.050) and HOMA-B (P = 0.046) with adjusting for age and body mass index in female normal subjects.
CONCLUSIONS: We conclude that genetic variants of TLR4 are associated with type 2 diabetes in the Chinese population, especially in female subjects.
© 2014 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  genetic polymorphisms; toll-like receptor 4; type 2 diabetes mellitus; 关键词:基因多态性,toll样受体4,2型糖尿病

Mesh:

Substances:

Year:  2014        PMID: 25104099     DOI: 10.1111/1753-0407.12206

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  7 in total

1.  Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease.

Authors:  Chun Wang; Jianping Gong; Hao Wu
Journal:  Biomed Rep       Date:  2017-06-14

2.  Quantitative assessment of TLR4 gene polymorphisms and T2DM risk: A meta-analysis.

Authors:  Jinzhuo Fan; Renxian Liang
Journal:  Mol Genet Genomic Med       Date:  2020-08-21       Impact factor: 2.183

3.  Association of TLR4 gene polymorphisms with childhood Henoch-Schönlein purpura in a Chinese population.

Authors:  Hui Xu; Guizhen Jiang; Hongqiang Shen; Wei Li; Jianhua Mao; Yanxiang Pan
Journal:  Rheumatol Int       Date:  2017-09-13       Impact factor: 2.631

4.  Toll-like receptor 4 rs11536889 is associated with angiographic extent and severity of coronary artery disease in a Chinese population.

Authors:  Dandan Sun; Yupeng Wu; Honghu Wang; Hong Yan; Wen Liu; Jun Yang
Journal:  Oncotarget       Date:  2017-01-10

5.  Opposite Genetic Effects of CMIP Polymorphisms on the Risk of Type 2 Diabetes and Obesity: A Family-Based Study in China.

Authors:  Yaying Cao; Tao Wang; Yiqun Wu; Juan Juan; Xueying Qin; Xun Tang; Tao Wu; Yonghua Hu
Journal:  Int J Mol Sci       Date:  2018-03-28       Impact factor: 5.923

6.  TLR4 polymorphisms may increase susceptibility to periodontitis in Pg-positive individuals.

Authors:  Wenjing Li; Xiaojing Cao; Lu He; Huanxin Meng; Bingtao Yang; Yanting Liao
Journal:  PeerJ       Date:  2019-11-21       Impact factor: 2.984

7.  Toll-Like Receptor 4 Activation Contributes to Diabetic Bladder Dysfunction in a Murine Model of Type 1 Diabetes.

Authors:  Theodora Szasz; Camilla F Wenceslau; Beth Burgess; Kenia P Nunes; R Clinton Webb
Journal:  Diabetes       Date:  2016-09-20       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.